These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1814 related articles for article (PubMed ID: 18421054)
1. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. Saltz LB; Clarke S; Díaz-Rubio E; Scheithauer W; Figer A; Wong R; Koski S; Lichinitser M; Yang TS; Rivera F; Couture F; Sirzén F; Cassidy J J Clin Oncol; 2008 Apr; 26(12):2013-9. PubMed ID: 18421054 [TBL] [Abstract][Full Text] [Related]
2. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. Cassidy J; Clarke S; Díaz-Rubio E; Scheithauer W; Figer A; Wong R; Koski S; Lichinitser M; Yang TS; Rivera F; Couture F; Sirzén F; Saltz L J Clin Oncol; 2008 Apr; 26(12):2006-12. PubMed ID: 18421053 [TBL] [Abstract][Full Text] [Related]
3. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. Rothenberg ML; Cox JV; Butts C; Navarro M; Bang YJ; Goel R; Gollins S; Siu LL; Laguerre S; Cunningham D Ann Oncol; 2008 Oct; 19(10):1720-6. PubMed ID: 18550577 [TBL] [Abstract][Full Text] [Related]
4. Phase I/II study of capecitabine plus oxaliplatin (XELOX) plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer. Doi T; Boku N; Kato K; Komatsu Y; Yamaguchi K; Muro K; Hamamoto Y; Sato A; Koizumi W; Mizunuma N; Takiuchi H Jpn J Clin Oncol; 2010 Oct; 40(10):913-20. PubMed ID: 20462981 [TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Van Cutsem E; Rivera F; Berry S; Kretzschmar A; Michael M; DiBartolomeo M; Mazier MA; Canon JL; Georgoulias V; Peeters M; Bridgewater J; Cunningham D; Ann Oncol; 2009 Nov; 20(11):1842-7. PubMed ID: 19406901 [TBL] [Abstract][Full Text] [Related]
6. A randomized, phase II trial of standard triweekly compared with dose-dense biweekly capecitabine plus oxaliplatin plus bevacizumab as first-line treatment for metastatic colorectal cancer: XELOX-A-DVS (dense versus standard). Hurwitz H; Mitchell EP; Cartwright T; Kwok A; Hu S; McKenna E; Patt YZ Oncologist; 2012; 17(7):937-46. PubMed ID: 22622147 [TBL] [Abstract][Full Text] [Related]
7. Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: results of a large registry-based cohort analysis. Buchler T; Pavlik T; Melichar B; Bortlicek Z; Usiakova Z; Dusek L; Kiss I; Kohoutek M; Benesova V; Vyzula R; Abrahamova J; Obermannova R BMC Cancer; 2014 May; 14():323. PubMed ID: 24884897 [TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. Hochster HS; Hart LL; Ramanathan RK; Childs BH; Hainsworth JD; Cohn AL; Wong L; Fehrenbacher L; Abubakr Y; Saif MW; Schwartzberg L; Hedrick E J Clin Oncol; 2008 Jul; 26(21):3523-9. PubMed ID: 18640933 [TBL] [Abstract][Full Text] [Related]
9. First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study. Díaz-Rubio E; Gómez-España A; Massutí B; Sastre J; Abad A; Valladares M; Rivera F; Safont MJ; Martínez de Prado P; Gallén M; González E; Marcuello E; Benavides M; Fernández-Martos C; Losa F; Escudero P; Arrivi A; Cervantes A; Dueñas R; López-Ladrón A; Lacasta A; Llanos M; Tabernero JM; Antón A; Aranda E; Oncologist; 2012; 17(1):15-25. PubMed ID: 22234633 [TBL] [Abstract][Full Text] [Related]
10. Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II). Hoff PM; Hochhaus A; Pestalozzi BC; Tebbutt NC; Li J; Kim TW; Koynov KD; Kurteva G; Pintér T; Cheng Y; van Eyll B; Pike L; Fielding A; Robertson JD; Saunders MP J Clin Oncol; 2012 Oct; 30(29):3596-603. PubMed ID: 22965965 [TBL] [Abstract][Full Text] [Related]
11. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. de Gramont A; Van Cutsem E; Schmoll HJ; Tabernero J; Clarke S; Moore MJ; Cunningham D; Cartwright TH; Hecht JR; Rivera F; Im SA; Bodoky G; Salazar R; Maindrault-Goebel F; Shacham-Shmueli E; Bajetta E; Makrutzki M; Shang A; André T; Hoff PM Lancet Oncol; 2012 Dec; 13(12):1225-33. PubMed ID: 23168362 [TBL] [Abstract][Full Text] [Related]
12. Comparison of first-line bevacizumab in combination with mFOLFOX6 or XELOX in metastatic colorectal cancer. Vedat Bayoglu I; Yildiz I; Varol U; Cokmert S; Kucukzeybek Y; Alacacioglu A; Demir L; Dirican A; Akyol M; Yildiz Y; Oktay Tarhan M J BUON; 2015; 20(2):460-7. PubMed ID: 26011336 [TBL] [Abstract][Full Text] [Related]
13. Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study. Saltz LB; Clarke S; Díaz-Rubio E; Scheithauer W; Figer A; Wong R; Koski S; Lichinitser M; Yang TS; Rivera F; Couture F; Sirzén F; Cassidy J J Clin Oncol; 2023 Jul; 41(21):3663-3669. PubMed ID: 37459755 [TBL] [Abstract][Full Text] [Related]
14. Commentary on a phase III trial of bevacizumab plus XELOX or FOLFOX4 for first-line treatment of metastatic colorectal cancer: the NO16966 trial. Tyagi P; Grothey A Clin Colorectal Cancer; 2006 Nov; 6(4):261-4. PubMed ID: 17241510 [TBL] [Abstract][Full Text] [Related]
15. Bevacizumab in Combination With Either FOLFOX-4 or XELOX-2 in First-line Treatment of Patients With Metastatic Colorectal Cancer: A Multicenter Randomized Phase II Trial of the Gruppo Oncologico dell'Italia Meridionale (GOIM 2802). Maiello E; Di Maggio G; Cordio S; Cinieri S; Giuliani F; Pisconti S; Rinaldi A; Febbraro A; Latiano TP; Aieta M; Rossi A; Rizzi D; Di Maio M; Colucci G; Bordonaro R Clin Colorectal Cancer; 2020 Jun; 19(2):109-115. PubMed ID: 32089455 [TBL] [Abstract][Full Text] [Related]
16. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. Giantonio BJ; Catalano PJ; Meropol NJ; O'Dwyer PJ; Mitchell EP; Alberts SR; Schwartz MA; Benson AB; J Clin Oncol; 2007 Apr; 25(12):1539-44. PubMed ID: 17442997 [TBL] [Abstract][Full Text] [Related]
17. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. Douillard JY; Siena S; Cassidy J; Tabernero J; Burkes R; Barugel M; Humblet Y; Bodoky G; Cunningham D; Jassem J; Rivera F; Kocákova I; Ruff P; Błasińska-Morawiec M; Šmakal M; Canon JL; Rother M; Oliner KS; Wolf M; Gansert J J Clin Oncol; 2010 Nov; 28(31):4697-705. PubMed ID: 20921465 [TBL] [Abstract][Full Text] [Related]
18. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer. Ducreux M; Bennouna J; Hebbar M; Ychou M; Lledo G; Conroy T; Adenis A; Faroux R; Rebischung C; Bergougnoux L; Kockler L; Douillard JY; Int J Cancer; 2011 Feb; 128(3):682-90. PubMed ID: 20473862 [TBL] [Abstract][Full Text] [Related]
19. Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group. Schmiegel W; Reinacher-Schick A; Arnold D; Kubicka S; Freier W; Dietrich G; Geißler M; Hegewisch-Becker S; Tannapfel A; Pohl M; Hinke A; Schmoll HJ; Graeven U Ann Oncol; 2013 Jun; 24(6):1580-7. PubMed ID: 23463625 [TBL] [Abstract][Full Text] [Related]
20. Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial. Yamada Y; Takahari D; Matsumoto H; Baba H; Nakamura M; Yoshida K; Yoshida M; Iwamoto S; Shimada K; Komatsu Y; Sasaki Y; Satoh T; Takahashi K; Mishima H; Muro K; Watanabe M; Sakata Y; Morita S; Shimada Y; Sugihara K Lancet Oncol; 2013 Dec; 14(13):1278-86. PubMed ID: 24225157 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]